Pathos AI has joined forces with pharmaceutical giant Bristol Myers Squibb and data specialist Tempus AI in a collaboration to develop advanced artificial intelligence tools aimed at accelerating drug discovery for Alzheimer’s and other neurological disorders. This partnership is backed by a significant $237 million Series E funding round valuing Pathos AI at $3 billion.
- Pathos AI secured $237M funding led by Bristol Myers valuing it at $3B
- Tempus AI to create a neurological patient dataset licensed to Pathos for $55M
- Bristol Myers gets strategic and exclusive access to AI drug development tools
What happened
Pathos AI announced a collaboration with Bristol Myers Squibb and Tempus AI to develop innovative artificial intelligence tools focused on drug development for Alzheimer’s disease and other neurological conditions. As part of the partnership, Tempus will construct a comprehensive dataset from hundreds of thousands of patients with neurological disorders to aid in tracking outcomes and advancing disease biology research.
Pathos AI will license this dataset under a $55 million, five-year agreement and utilize its AI platform, Pathos Foundry, to analyze the data at scale. This platform will help generate hypotheses, test disease mechanisms, and design more adaptive and targeted clinical trials. Additionally, Bristol Myers gained non-exclusive access to Pathos Foundry for its broader portfolio and exclusive three-year rights for its neuroscience programs.
Why it matters
The collaboration marks a significant step in harnessing artificial intelligence to accelerate the development of therapies for complex neurological disorders like Alzheimer’s, a field where breakthroughs have been challenging to achieve. By combining Tempus’ extensive medical datasets with Pathos AI’s powerful analytical capabilities, the partners aim to deepen understanding of disease progression and improve clinical trial efficiency.
The $237 million funding round led by Bristol Myers, which now values Pathos AI at around $3 billion, will enable Pathos to expand its AI platform capabilities and accelerate its pipeline of AI-driven experimental therapies. This includes advancing a novel cancer drug, JSKN016, as well as other oncology programs in collaboration with AstraZeneca, illustrating the broader potential impact of their AI-driven approach beyond neuroscience.
What to watch next
Industry observers should monitor the progress of Pathos AI’s application of their AI platform to the neurological disorder dataset and how effectively it translates into improved clinical trial designs and new drug candidates. Progress in Alzheimer’s drug development will be particularly important given the disease’s growing global burden and the high unmet medical need.
Additionally, the deployment of Pathos AI’s platform across Bristol Myers’ wider portfolio, including exclusive neuroscience programs, and the advancement of experimental oncology drugs like JSKN016 will be key developments. These will demonstrate the scalability and versatility of artificial intelligence in drug development across multiple therapeutic areas.